

---

# Midazolam in Pediatric Dentistry

---

Ashwin Rao • Shweta Tiwari

# Midazolam in Pediatric Dentistry

Ashwin Rao  
Manipal College of Dental  
Sciences Mangalore  
Manipal Academy of Higher Education  
Manipal, India

Shweta Tiwari  
Tiny Teeth-Children  
Teens and Special Needs Dentistry  
Mangaluru, India

ISBN 978-3-031-45146-1      ISBN 978-3-031-45147-8 (eBook)  
<https://doi.org/10.1007/978-3-031-45147-8>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2024

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG  
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Paper in this product is recyclable.

---

## Foreword

In the world of Pediatric Dentistry, ensuring the well-being and comfort of young patients is of paramount importance. This generation of children and their parents walk into our practices with different expectations from Pediatric Dentistry, thus throwing new challenges. As practitioners in this field, we are continually searching for ways to alleviate anxiety, reduce pain, and create positive dental experiences for children. It is with great pleasure that I introduce this comprehensive and insightful book on *Midazolam in Pediatric Dentistry*.

Midazolam, a well-known sedative with good margin of safety, has emerged as a valuable tool in our efforts to make dental visits more pleasant for children. This book, authored by Dr. Ashwin Rao and Dr. Shweta Tiwari, experts in the field, explores the various aspects of minimal and moderate sedation using midazolam in Pediatric Dentistry, from its pharmacological properties to practical clinical applications.

The authors have gone to great lengths to share their expertise, providing a detailed account of the drug's mechanism of action, appropriate dosages, and administration techniques. They also discuss the critical importance of patient selection and evaluation, ensuring that midazolam is used safely and effectively.

As you delve into the pages of this book, a first of its kind and very focused on the topic, you will find not only a wealth of information but also practical insights into case selection where midazolam can make a significant difference in the lives of young dental patients. The book will underscore the genuine impact that this drug can have in Pediatric Dentistry, transforming what might otherwise be a daunting experience into one that is manageable and even pleasant.

In today's world, Pediatric Dentists and their teams strive to provide holistic care that prioritizes the physical and emotional needs of children. Midazolam is a crucial tool in achieving this goal, and this book serves as a valuable guide for those looking to enhance their practices and improve the lives of young patients.

I commend the authors Dr. Ashwin Rao and Dr. Shweta Tiwari for their dedication and expertise in compiling this important resource. It is my hope that this book will not only educate and inform but also inspire those in the field of Pediatric Dentistry to continue pushing the boundaries of what is possible in delivering compassionate and effective care.

Rainbow Children's Hospital  
Hyderabad, Telangana, India

Dr. Srinivas Namineni,  
MDS (Pediatric and Preventive Dentistry)

---

## Preface

“*Sedation*” caught our imagination very early in our career in Pediatric Dentistry. We realized that we were duty bound to provide anxious children, with high-quality pain-free treatment even when their age and cognition did not allow them to cooperate for demanding dental procedures. Inhalation sedation with nitrous oxide and oxygen helped us fulfill this objective more often than not. But yet, we learnt in the steep learning curve of procedural sedation that a small group of children cannot comprehend the nasal hood and require other modes to help them through. We worked with various drugs like chloral hydrate, hydroxyzine, midazolam, dexmedetomidine, etc., only to find inconsistent success. Experience gradually taught us that understanding the limitations of these drugs was as important as understanding their indications and advantages. We also learnt that success with sedation should not come at the cost of unintentional deep sedation or the associated risks. As we worked more with midazolam with an understanding of its limitations, this drug started revealing its magic in terms of producing reliable, consistent, and safe anxiolysis, sedation, and amnesia along with a host of other advantages. Proper case selection in conjunction with a good local anesthetic technique proved to be the game changers in this journey.

But, as we shared our successful experiences with this drug at various professional forums, we observed that many of our Pediatric Dentist colleagues were only finding their feet with the use of midazolam. They in their effort to provide the highest quality of dental care to children had various queries on its practical application in practice including case selections, safety, routes of administration, timing of its use, role of behavior guidance, and local anesthesia. We felt a need to bridge this lacunae between theoretical knowledge and the actual effective use of midazolam in clinical Pediatric Dentistry. Therein conceptualized the idea of penning a structured work on the subject eventually leading to the genesis of this textbook. We have nine thoughtfully written chapters and numerous hand drawn figures (Credits: Dr. Shweta Tiwari) in the book. Each chapter has been written with a specific objective to help the reader enhance her/his understanding of “Sedation with Midazolam” and gain confidence in its use.

Here we would like to express our heartfelt gratitude to Dr. Srinivas Namineni, Pediatric Dentist, Rainbow Children’s Hospital Hyderabad, a pioneer of dental sedation in India who flagged us off on this journey of sedation in Pediatric Dentistry. He was kind enough to consent writing the foreword for this work. We also remain

grateful to the entire Indian Pediatric Dental community for always encouraging us through this exciting undertaking.

We dedicate this book to our entire family whose unconditional love and support gave us the time to focus, deliberate, write and rewrite every chapter leading to the treatise that you are now reading.



Mangaluru, India

Ashwin Rao



December 2023

Shweta Tiwari

---

# Contents

<b>1</b>	<b>The Practical Role of Midazolam in Pediatric Dentistry</b>	<b>1</b>
1.1	Overview	1
1.2	Background and Objective	1
1.3	Need for Pharmacological Management in Children	2
1.4	The Role of Inhalation Sedation and Other Sedative Drugs	2
1.5	The Benzodiazepines	3
1.5.1	Classification of Benzodiazepines and their Clinical Applications	3
1.6	Midazolam	3
1.6.1	Desirable Characteristics of Midazolam	4
1.6.2	Midazolam: A Minimal and Moderate Sedation Drug	5
1.6.3	Deep Sedation with Midazolam	5
	References	7
<b>2</b>	<b>Understanding Midazolam: The Key to Its Safe Clinical Use</b>	<b>9</b>
2.1	Overview	9
2.2	Background and Objective	9
2.3	Chemistry	9
2.3.1	Importance of Understanding the Chemistry of Midazolam	9
2.3.2	The Basic Chemical Structure of Midazolam	10
2.3.3	Water Solubility of Midazolam Related to its Chemical Structure	11
2.3.4	The Clinical Advantages of the Water Solubility of Midazolam	12
2.3.5	The Chemical Structure of Midazolam Influencing its Quick Onset and Short Duration of Clinical Action	12
2.4	Pharmacokinetics	12
2.4.1	Lipophilicity of Midazolam	12
2.4.2	Midazolam's Quick Onset of Clinical Action	13
2.4.3	Understanding Basics of Drug Metabolism	14
2.4.4	The Short Duration of Clinical Action of Midazolam	14
2.4.5	Other Clinically Relevant Information Related to Midazolam Metabolism in the Liver	14

2.4.6	Alpha and Beta Half-Life of Midazolam . . . . .	15
2.4.7	Brief Note on Excretion . . . . .	16
2.5	Pharmacodynamics . . . . .	16
2.5.1	Difference Between Sedation, Hypnosis, and Anxiolysis . . . . .	16
2.5.2	GABA . . . . .	16
2.5.3	The GABA Receptors . . . . .	16
2.5.4	Reason for the High Therapeutic Index and Safety Profile of Benzodiazepines . . . . .	17
2.5.5	Sedative-Hypnotic, Amnestic, and Anticonvulsive Effects of Midazolam . . . . .	18
2.5.6	Anxiolytic and Muscle Relaxant Effects of Midazolam . . . .	19
2.5.7	The Low Incidence of Benzodiazepine-Associated Respiratory Depression . . . . .	19
2.5.8	Anterograde Amnestic Property of Midazolam and its Clinical Relevance . . . . .	20
2.5.9	Paradoxical Reactions . . . . .	20
	References . . . . .	21
3	<b>Pre-operative Assessment: The Key to Safe Sedation Outcomes . . . .</b>	23
3.1	Overview . . . . .	23
3.2	Background and Objective . . . . .	23
3.3	ASA Classification and its Importance in Sedation . . . . .	24
3.4	Steps to Arrive at an ASA Category for the Child . . . . .	24
3.4.1	Structured Medical History . . . . .	25
3.4.2	Evaluation of Vital Signs . . . . .	25
3.4.3	Body Mass Index (BMI)-for-Age Percentiles . . . . .	28
3.4.4	Tonsil Size and Extra-Oral Anatomic Abnormalities . . . . .	29
3.4.5	Mallampati Classification . . . . .	31
3.4.6	Recent History of Upper Respiratory Tract Infection (URTI) . . . . .	32
3.4.7	Auscultation of the Heart and the Lungs . . . . .	33
3.4.8	The Sedation Plan Based on the ASA Category . . . . .	41
	References . . . . .	42
4	<b>Basic and Advanced Behavior Guidance Templates Based on the Frankl Behavior Rating Scale . . . . .</b>	45
4.1	Overview . . . . .	45
4.2	Background and Objective . . . . .	45
4.3	Frankl Behavioral Rating Scale . . . . .	46
4.4	Traits of the Frankl Behavior Rating Categories and their Suggested Behavior Guidance Templates . . . . .	47
4.4.1	Rating 4: Definitely Positive . . . . .	47
4.4.2	Rating 3: Positive . . . . .	47
4.4.3	Rating 2: Negative . . . . .	48
4.4.4	Rating 1: Definitely Negative . . . . .	50
4.5	Indications of Midazolam in a Nutshell . . . . .	57
	References . . . . .	59



<b>5</b>	<b>Routes of Midazolam Administration</b>	<b>61</b>
5.1	Overview	61
5.2	Background and Objective	61
5.3	Where Should the Sedative Drug Be Administered?	62
5.4	Volume of Drug Distribution and Midazolam Dosage	62
5.5	Intravenous Route of Midazolam Administration	63
5.5.1	The Practical Role of Intravenous Midazolam in Pediatric Dentistry	63
5.5.2	Advantages	64
5.5.3	Disadvantages	64
5.5.4	Equipment for Intravenous Infusion	64
5.5.5	Administration	70
5.5.6	Onset of Action	72
5.6	The Concept of “Titration by Appointment” for Other Routes	72
5.7	The Oral Route of Midazolam Administration	72
5.7.1	The NPO and the Oral Route	73
5.7.2	Advantages	73
5.7.3	Disadvantages	73
5.7.4	Dosage	74
5.7.5	Administration	74
5.7.6	Onset of Action	76
5.8	Intranasal Route of Midazolam Administration	77
5.8.1	Advantages Over the Oral Route	77
5.8.2	Disadvantages	77
5.8.3	Dosage	78
5.8.4	Administration	78
5.8.5	Onset of Action	79
5.9	Intramuscular Route of Midazolam Administration	80
5.9.1	Advantages	80
5.9.2	Disadvantages	80
5.9.3	Dosage	81
5.9.4	Administration	81
5.9.5	Onset of Action	82
5.10	Rectal Route of Midazolam Administration	82
5.10.1	Advantages	82
5.10.2	Disadvantages	83
5.10.3	Dosage	83
5.10.4	Technique of Administration	83
5.10.5	Onset of Action	84
5.11	Oral Mucosal Route of Midazolam Administration	84
5.11.1	Advantages	84
5.11.2	Disadvantages	84
5.11.3	Dosage	85
5.11.4	Technique of Administration	85
5.11.5	Onset of Action	86
	References	88

<b>6</b>	<b>Local Anesthetic Techniques in Children</b>	91
6.1	Overview	91
6.2	Background and Objective	91
6.3	The Philosophy of Local Anesthesia in Children	92
6.4	Are “Painless” Intraoral Injections Possible?	93
6.5	The Process	93
6.5.1	Establishing Two-Way Communication	94
6.5.2	Use of Euphemisms	94
6.5.3	Instructions to the Parents	95
6.5.4	Applying the Topical Anesthetic	96
6.5.5	Needle Selection and Assembling the Syringe	97
6.5.6	Keeping the Syringe Out of the Child’s Line of Sight	97
6.5.7	Needle Insertion	98
6.5.8	Slow Deposition of the Local Anesthetic Solution	99
6.5.9	Use of Distraction, Verbal Positive/Negative Reinforcement, and Voice Modulation During the Injection Process	100
6.6	Local Anesthetic Techniques in Children	101
6.6.1	The Buccal/Labial Supraperiosteal Injection	101
6.6.2	Palatal Anesthesia with the Intra-papillary Technique	104
6.6.3	The Modified Two-Stage Inferior Alveolar Nerve Block (IANB) Technique	106
6.7	Additional Considerations for Local Anesthesia in Children	111
6.7.1	Injection in the Maxillary Second Primary/First Permanent Molar Region	111
6.7.2	Maximum Recommended Dosage (MRD)	112
6.7.3	Effectiveness of Mandibular Molar Supraperiosteal Injections in Children	112
6.7.4	Buffering the Local Anesthetic Solution	113
	References	115
<b>7</b>	<b>Midazolam: A Step-by-Step Clinical Protocol</b>	119
7.1	Overview	119
7.2	Background and Objective	119
7.3	The Objective Signs of Sedation	120
7.4	Parental Presence Inside the Operatory	121
7.5	“Settling” the Child	121
7.6	Nitrous Oxide and Oxygen	121
7.7	Protective Stabilization	122
7.8	Personnel and Monitoring	124
7.8.1	Personnel	124
7.8.2	Types and Frequency of Monitoring	124
7.8.3	Level of Consciousness	125
7.8.4	Monitoring Equipment	126
7.9	Administration of Local Anesthesia	129

7.10	Rubber Dam Application for Restorative Procedures . . . . .	130
7.11	Discharge Criteria . . . . .	130
7.12	Post-Operative Instructions to Parents . . . . .	131
	References . . . . .	132
<b>8</b>	<b>SAFE: Sedation Attitudes to Forestall Emergencies . . . . .</b>	<b>135</b>
8.1	Overview . . . . .	135
8.2	Background and Objective . . . . .	135
8.3	Ground Rules Governing the Safe Practice of Sedation in Pediatric Dentistry . . . . .	136
8.3.1	A Meticulous Pre-operative Assessment . . . . .	136
8.3.2	Strict “Nil per Oral” ( <i>NPO</i> ) Compliance . . . . .	136
8.3.3	“Single Drug-Single Dose” . . . . .	137
8.3.4	Understanding Deep Sedation/General Anesthesia and Moderate Sedation . . . . .	139
8.3.5	Following the Recommended Monitoring, Personnel, and Infrastructure Protocols for the Planned Level of Sedation . . . . .	142
8.3.6	Following the Recovery and Discharge Protocols . . . . .	143
8.4	Management of Sedation-Related Emergencies . . . . .	143
8.4.1	The Two Potential Complications of Moderate Sedation . . . . .	143
8.4.2	Basic Management of Desaturation in a Deeply Sedated Child . . . . .	144
8.4.3	Diagnosing the Complication and Management in a Continued Desaturation Scenario . . . . .	144
8.4.4	Assisted Positive Pressure Ventilation . . . . .	145
8.4.5	The Oropharyngeal Airway . . . . .	146
8.4.6	The Use of a Laryngeal Mask Airway . . . . .	148
8.4.7	The Administration of Flumazenil . . . . .	149
8.4.8	The Administration of Adrenaline . . . . .	149
8.4.9	The Initiation of Cardiac Compressions . . . . .	149
8.4.10	Management of Intraoperative Vomiting . . . . .	150
8.4.11	List of Emergency Drugs and Equipments . . . . .	150
	References . . . . .	152
<b>9</b>	<b>Documentation . . . . .</b>	<b>155</b>
9.1	Overview . . . . .	155
9.2	Background and Objective . . . . .	155
9.3	Drug Procurement . . . . .	155
9.4	Pre-operative Documentation . . . . .	156
9.4.1	Pre-operative Assessment Records . . . . .	156
9.4.2	Informed Consent . . . . .	156
9.4.3	Pre-operative Parent Instructions . . . . .	157
9.5	Intraoperative Documentation . . . . .	157

---

9.6	Post-operative Documentation . . . . .	158
9.6.1	Discharge Criteria . . . . .	158
9.6.2	Post-operative Parent Instructions and Discharge Summary . . . . .	158
	Annexure 1: Pre-operative Assessment. . . . .	159
	Annexure 2: Informed Consent Form for Midazolam Sedation . . . . .	161
	Annexure 3: Pre-operative Parent Instructions . . . . .	162
	Annexure 4: Intraoperative Documentation . . . . .	163
	Annexure 5: Discharge Criteria . . . . .	165
	Annexure 6: Post-operative Parent Instructions and Discharge Summary . . . . .	165
	References. . . . .	166



# The Practical Role of Midazolam in Pediatric Dentistry

1

## 1.1 Overview

Midazolam has a definite role in the behavior guidance armamentarium of the Pediatric Dentist. But to make its use predictable and consistent requires not only an in-depth understanding of the drug but also an understanding of its limitations. This introductory chapter deals with the need for pharmacological management in children, the roles of midazolam and inhalation sedation, and the unique properties that make midazolam an almost ideal sedative agent in Pediatric Dentistry. This chapter also helps the reader appreciate that midazolam in prescribed doses will lead to minimal/moderate sedation only. Minimal/moderate sedation won't be able to overcome the extreme fear of a combative child. Hence, midazolam on its own will *not* be effective in combative children. It will work best for anxious children in conjunction with non-pharmacological behavior guidance and good local anesthetic techniques, which are ultimately the cornerstones of child management in Pediatric Dentistry.

## 1.2 Background and Objective

Midazolam is currently the dental sedative of choice in children [1]. But numerous questions accompany its use among clinicians learning the ropes of sedation (Fig. 1.1).

The objective of this introductory chapter will be to address these questions in a nutshell and elaborate upon them in the subsequent chapters.



**Fig. 1.1** Questions accompanying the use of midazolam in Pediatric Dentistry

---

### **1.3 Need for Pharmacological Management in Children**

Non-pharmacological behavior guidance with good local anesthetic techniques is still the cornerstone of child management in Pediatric Dentistry. But it cannot be denied that dental treatment even for the most cooperative child can be anxiety provoking and intimidating. This is where pharmacological management steps in, helping anxious children cope up positively with the treatment.

---

### **1.4 The Role of Inhalation Sedation and Other Sedative Drugs**

Inhalation sedation with nitrous oxide and oxygen along with non-pharmacological behavior guidance and local anesthesia completes the powerful troika of behavior guidance tools capable of managing most apprehensive children. But inhalation sedation requires the child to sportingly wear the nasal hood. Most children do that with good communicative behavior guidance. But age, extreme anxiety, and an inability to comprehend instructions impede many children from doing so. This is where the need for other drugs come into play. Drugs, which will sedate the child predictably for short procedures or facilitate the acceptance of the nasal hood for long procedures. A long list of prospective drug classes become relevant in this space. Benzodiazepines, barbiturates, opioids, antihistamines, and other drugs like

ketamine are the frontrunners. Among these, the benzodiazepine class of drugs have currently established themselves as the most effective oral anxiolytic drugs [2].

---

## 1.5 The Benzodiazepines

The discovery of chlordiazepoxide, the first drug in the benzodiazepine class, in 1957 by L. H. Sternbach and L. O. Randall represents a milestone in the journey of psychoactive drugs. It leads the way for the synthesis of more than 2000 benzodiazepines ever since [2].

The popularity of benzodiazepines is because of their high therapeutic index. The therapeutic index signifies the relative safety of the drug. It is a comparison of the dosage of the drug that will bring about the desired effect as opposed to the dosage triggering severe side effects [3]. In other words, benzodiazepines have a wide margin of safety. The availability of an antagonist flumazenil also adds to the safety profile of benzodiazepines [4].

### 1.5.1 Classification of Benzodiazepines and their Clinical Applications

This big family of benzodiazepine drugs are broadly classified as benzodiazepine antianxiety agents and benzodiazepine sedative hypnotic agents [2].

The antianxiety agents are commonly used for pretreatment anxiolysis in adults. They are intended to produce the “minimal” level of sedation usually without impairing the mental alertness, psychomotor performance, and ventilator or cardiovascular performance. Oxazepam and diazepam are popular drugs in this category. Diazepam introduced in 1963 is considered the poster boy of this benzodiazepine subcategory and still continues to be a very popular drug in this category.

The benzodiazepine sedative hypnotic agents manifest sedation, clinically producing a calming effect along with drowsiness and ataxia. Higher doses of this group of drugs produce hypnosis or sleep. Midazolam and triazolam are the popular drugs in this category. Triazolam is commonly prescribed as a sedative/hypnotic in adults, whereas midazolam is currently the dental sedative of choice in children [1].

---

## 1.6 Midazolam

Midazolam was first synthesized by Walser and Fryer at Hoffmann-La Roche, Inc., in the United States in the year 1976 [5]. It inherits all the desired pharmacological actions of benzodiazepines including anxiolysis, sedation, hypnosis, anticonvulsant properties, muscle relaxant properties, and the ability to produce anterograde amnesia [6]. In addition, it brings to the table several unique properties of its own. These unique properties have propelled it to be the most extensively used drug for pediatric procedural sedation [7]. More specifically, in Pediatric Dentistry, it is the

most commonly used sedative agent with the exception of nitrous oxide and oxygen [8].

### 1.6.1 Desirable Characteristics of Midazolam

The high water solubility facilitates its intravenous/intramuscular injection without any local irritation [9]. Its water solubility also makes it nonirritant to the mucosa enabling the administration of the injectable solution orally, rectally, or nasally. The injectable solution can be flavored to be administered orally in case commercial oral formulations are not available [10]. This interesting water solubility aspect in the chemistry of midazolam along with its pharmacokinetics and pharmacodynamics has been discussed in detail in Chap. 2.

The rapid absorption, onset of action, and rapid metabolism without the “rebound” effect seen with diazepam makes it an ideal short-acting agent for dental procedures in children. It can be used as a primary anxiolytic and sedative for short procedures or can be safely combined as a premedication prior to inhalation sedation with nitrous oxide and oxygen for long procedures [11]. The short period of clinical action also facilitates a faster discharge, thereby also saving clinical time in a busy practice.

Its availability in various forms as injectable solutions, syrups, tablets, and sprays makes it a versatile drug compatible with multiple routes of drug administration (See Chap. 5). The Pediatric Dentist can choose the most appropriate route depending on the child’s behavior.

The other desirable properties of midazolam making it an attractive proposition for Pediatric Dentistry are:

*Anxiolysis and Sedation:* Most alternatives to midazolam for moderate sedation like meperidine, hydroxyzine, ketamine, or dexmedetomidine have primary clinical indications, which are *not* anxiolysis and sedation. Meperidine, for example, is primarily an analgesic. Sedation is its secondary clinical effect activated at higher doses. The same holds good for hydroxyzine, which is essentially an antihistamine. Ketamine is a general anesthetic drug, and dexmedetomidine is intended as a premedication to facilitate general anesthesia or intravenous cannulation. Midazolam on the other hand is manufactured to be used as an anxiolytic and sedative.

*Antianxiety Properties:* It is very important to differentiate concepts of anxiolysis, sedation, and hypnosis. Anxiolysis is the anxiety relief or “calming effect” obtained after administration of an anxiolytic medication. Sedation literally translates to drowsiness, whereas hypnosis is natural sleep. Midazolam possesses all the three properties depending on the dosage administered. But it is the anxiolytic property with the minimal/moderate sedation that it causes, which makes it a useful pharmacological agent in Pediatric Dentistry. It calms the anxious child and causes mild drowsiness creating a conducive environment to implement basic behavior guidance techniques.

*Anterograde Amnesia:* Though anxiolysis and mild sedation continue to be the primary reasons for choosing midazolam, its ability to cause anterograde amnesia is



especially useful in children during stressful procedures like local anesthesia. The child may still cry during the local anesthetic administration due to the lack of analgesic properties in midazolam. But, post procedure, the child may not remember how the soft tissues got numb. This property of lack of recall after administration of midazolam is called anterograde amnesia.

*Wide Therapeutic Margin:* Midazolam has a high safety index. This is because of the wide margin in the dose of midazolam that causes the desired clinical effect to the dose that can cause a complication.

*Muscle Relaxant and Anticonvulsant Properties:* The muscle relaxant property facilitates a more comfortable mouth opening and insertion of a mouth-restraining device like a molt prop. The anticonvulsant property is an additional bonus in epileptic children or during a seizure episode secondary to a local anesthetic over dosage.

### 1.6.2 Midazolam: A Minimal and Moderate Sedation Drug


We should be absolutely clear at this point that midazolam, regardless of the route of administration, is a drug safely intended at recommended doses, only for minimal/moderate sedation. The concept of “minimal to moderate” sedation underlines that the drug will only help an anxious child cope up with the stress of dental treatment. Minimal/moderate sedation drugs will not be able to override the extreme fear of a combative child. They will work best in conjunction with good local anesthetic techniques, which in turn will require the clinician to use the entire gambit of non-pharmacological behavior guidance techniques. The concept of “minimal to moderate” sedation is therefore essentially a triangle where these three components are interrelated (Fig. 1.2).

The above concept is explained in detail in Chap. 6.

A combative child with a true objective fear towards dentistry may try and fight the anxiolytic (calming) effect of midazolam. This may lead to a paradoxical reaction with the child becoming more aggressive and fearful instead of calming down [12]. Hence, minimal/moderate sedation drugs like midazolam should *not* be expected to be effective in combative children or those displaying disruptive behavior. These children are best treated under deep sedation or general anesthesia. The only exception to this rule could be pre-cooperative children (3 years or less) requiring short procedures like extractions.

### 1.6.3 Deep Sedation with Midazolam

Deep sedation is also possible with midazolam by increasing its dosage or by combining it with other sedatives. But the clinician should be aware that deep sedation or essentially an ultra-light plane of general anesthesia [13] may also bring with it life-threatening complications like desaturations, respiratory depression, or loss of protective reflexes [14]. If the clinician desires deep sedation to treat a combative/disruptive child with objective fears, then there are other suitable drugs like



**Fig. 1.2** Triangle depicting the importance of sound local anesthetic and non-pharmacological behavior guidance techniques for effective minimal/moderate sedation

propofol and ketamine which will do the job. These drugs in the experienced hands of an anesthetist will provide deep sedation safely at smaller dosages.

The concepts discussed in the paragraph above are explained elaborately in Chaps. 4 and 8.

We will strive to explain in further chapters the predictable ways to achieve minimal/moderate sedation through midazolam in children. Proper systemic history (Chap. 3), the correct intraoperative protocol (Chap. 7), and meticulous documentation (Chap. 9) are the roadmaps through which midazolam can become a valuable asset in the child management armamentarium of the Pediatric Dentist.

#### Clinically Relevant Points

1. Midazolam is the most commonly used sedative agent in Pediatric Dentistry with the exception of nitrous oxide and oxygen.
2. The rapid absorption, onset of action, and rapid metabolism without the “rebound” effect seen with diazepam makes midazolam an ideal short-acting agent for dental procedures in children.
3. Midazolam will sedate an anxious child predictably for short procedures or will facilitate the acceptance of the nasal hood for long procedures.
4. Midazolam has a high therapeutic index and hence a wide margin of safety.

5. The water solubility of midazolam makes it nonirritant to the mucosa enabling the administration of the injectable solution orally, rectally, or nasally.
6. Midazolam regardless of the route of administration is a drug safely intended at recommended doses, only for minimal/moderate sedation.
7. Moderate sedation drugs like midazolam should *not* be expected to be effective in combative children or those displaying disruptive behavior.
8. Midazolam has to be used in conjunction with non-pharmacological methods of behavior guidance along with sound local anesthetic techniques.
9. Anxiolysis is the anxiety relief or “calming effect” obtained after administration of an anxiolytic medication. Sedation literally translates to drowsiness, whereas hypnosis is natural sleep. Midazolam possesses all the three properties depending on the dosage administered.
10. Though anxiolysis and mild sedation continue to be the primary reasons for choosing midazolam, its ability to cause anterograde amnesia is especially useful in children during stressful procedures like local anesthesia.
11. A combative child with a true objective fear towards dentistry may try and fight the anxiolytic (calming) effect of midazolam. This may lead to a paradoxical reaction with the child becoming more aggressive and fearful instead of calming down.
12. Deep sedation is also possible with midazolam by increasing its dosage or by combining it with other sedatives. But the clinician should be aware that deep sedation or essentially an ultra-light plane of general anesthesia may also bring with it life-threatening complications like desaturations, respiratory depression, or loss of protective reflexes.

---

## References

1. Wilson S. Minimal and moderate sedation agents. In: Wright GZ, Kupietzky A, editors. Behavior management in dentistry for children. 2nd ed. Wiley Blackwell; 2014. p. 159–75.
2. Malamed SF. Oral sedation. In: Sedation: a guide to patient management. 6th ed. St. Louis, Missouri: Elsevier; 2018. p. 95–119.
3. Trevor A, Katzung B, Masters S, Knudering-Hall M. Pharmacodynamics. In: Pharmacology examination & board review. 10th ed. New York: McGraw-Hill Medical; 2013. p. 17.
4. Glass PS, Jhaveri RM, Ginsberg B, Ossey K. Evaluation of flumazenil for reversing the effects of midazolam-induced conscious sedation or general anesthesia. South Med J. 1993;86(11):1238–47. <https://doi.org/10.1097/00007611-199311000-00011>.
5. Kupietzky A, Houpt MI. Midazolam: a review of its use for conscious sedation of children. Pediatr Dent. 1993;15(4):237–41.
6. Gao F, Wu Y. Procedural sedation in pediatric dentistry: a narrative review. Front Med (Lausanne). 2023;10:1,186,823. <https://doi.org/10.3389/fmed.2023.1186823>.